NASDAQ: BLTE - Belite Bio, Inc

六个月盈利: +42.68%
股息率: 0.00%
部门: Healthcare

促销时间表 Belite Bio, Inc

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients.

更多详情
The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2022-04-29
ISIN US07782B1044
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://belitebio.com
Цена ао 65.21
每日价格变化: +0.0598% (66.85)
每周价格变化: -0.5797% (67.28)
每月价格变化: +20.52% (55.5)
3个月内价格变化: +7.89% (62)
六个月内的价格变化: +42.68% (46.88)
每年价格变化: +74.33% (38.37)
年初以来价格变化: +7.94% (61.97)
所有参数

低估

姓名 意义 年级
P/S 0 0
P/BV 13.5 1
P/E 0 0
EV/EBITDA -36.24 0
全部的: 1.13

效率

姓名 意义 年级
ROA, % -33.42 0
ROE, % -34.98 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.0283 10
全部的: 9

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 0 0
盈利能力 Ebitda, % 453.14 10
盈利能力 EPS, % 398.1 10
全部的: 8
更多详情

机构 体积 分享, %
Armistice Capital, LLC 36000 0.12
Morgan Stanley 22421 0.08
State Street Corporation 17557 0.06
Cubist Systematic Strategies, LLC 16882 0.06
Marshall Wace LLP 16011 0.05
JP Morgan Chase & Company 14267 0.05
Point72 Asset Management, L.P. 7700 0.03
Geode Capital Management, LLC 6700 0.02
Jump Financial, LLC 5200 0.02
Renaissance Technologies, LLC 4900 0.02

ETF分享, %本年盈利能力, %股息, %
Virtus LifeSci Biotech Clinical Trials ETF 0.76712 63.04 0.33
SPDR S&P Emerging Markets Small Cap ETF 0.03878 5.46 3.03583
SPDR S&P China ETF 0.02029 17.02 3.40103
SPDR Portfolio Emerging Markets ETF 0.00475 11.59 3.1879
0.2124.282.49



导师 职称 支付 出生年份
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO N/A 1979 (46 年)
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director N/A 1985 (40 年)
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer N/A 1967 (58 年)
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board

地址: United States, San Diego. CA, 12750 High Bluff Drive - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://belitebio.com